45,185 results match your criteria Ulcerative Colitis


Adalimumab-Related Dental Implant Infection.

J Oral Maxillofac Surg 2019 Jan 30. Epub 2019 Jan 30.

Attending Surgeon, Division of Oral and Maxillofacial Surgery, Allegheny General Hospital, Pittsburgh, PA.

We present an adalimumab-related dental implant surgical-site infection. A 55-year-old patient with a history of twice-weekly adalimumab subcutaneous injections for ulcerative colitis underwent mandibular extractions and placement of 5 immediate dental implants. She experienced intraoral purulent drainage from all 5 dental implant sites with submental and submandibular space infections 2 weeks after surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.joms.2019.01.033DOI Listing
January 2019

Management of Biological Therapy Before Elective Inflammatory Bowel Disease Surgeries.

Inflamm Bowel Dis 2019 Feb 22. Epub 2019 Feb 22.

Division of Gastroenterology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Increasing uptake of biologic therapy has contributed to declining surgical rates for inflammatory bowel disease (IBD). However, a significant number of patients on biologic therapy will go on to require surgery. The literature is conflicted with regard to the preoperative management of biologic therapy before urgent or elective IBD surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz002DOI Listing
February 2019

Whole Exome Sequencing of Ulcerative Colitis-associated Colorectal Cancer Based on Novel Somatic Mutations Identified in Chinese Patients.

Inflamm Bowel Dis 2019 Feb 22. Epub 2019 Feb 22.

Department of Gastroenterology, Key Laboratory of Gut Microbiota Translational Medicine Research, Peking Union Medical College Hospital, Chinese Academy of Medical Science, No. 1 Shuaifuyuan, Beijing, China.

Background: Carcinogenesis is a severe consequence of chronic ulcerative colitis. We investigated the somatic mutations and pathway alterations in ulcerative colitis-associated colorectal cancer (CRC) in Chinese patients compared with sporadic CRCs to reveal potential therapeutic targets in ulcerative colitis-associated CRC.

Methods: Whole exome sequencing was performed on archival tumor tissues and paired adjacent nondysplastic mucosa from 10 ulcerative colitis-associated CRC patients at a high risk of carcinogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izz020DOI Listing
February 2019

Depression and resilience in ulcerative colitis and Crohn's disease patients with ostomy.

Int Wound J 2019 Mar;16 Suppl 1:62-70

Division of Colon and Rectal Surgery, Department of Surgery, ASAN Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

The purpose of this study is to identify the degree of depression and resilience in ulcerative colitis (UC) and Crohn's disease (CD) patients with ostomy and describe the correlation between depression and resilience in UC and CD patients with ostomy. 24 UC patients and 66 CD patients with ostomy were recruited from Metropolitan Hospital in Seoul, Korea. The total mean scores of depression and resilience in UC patients were 13. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/iwj.13076DOI Listing

Kidney Transplantation in Patients with Inflammatory Bowel Diseases (IBD): Analysis of Transplantation Outcome and IBD Activity.

Transpl Int 2019 Feb 21. Epub 2019 Feb 21.

Organ Transplantation Unit, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Inflammatory Bowel Diseases (IBD) is a systemic disorder with possible renal involvement, yet data regarding the outcome of kidney transplantation (KT) in those patients, and IBD course post KT, are scarce. In this retrospective analysis, we studied the outcome of 12 IBD kidney recipients (7 Crohn's disease, 5 ulcerative colitis; primary kidney disease was IgA nephropathy in 5, polycystic disease in 4), compared to two control groups: matched-controls, and a cohort of recipients with similar kidney disease. During a follow-up period of 60. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/tri.13415DOI Listing
February 2019

Perceived Quality of Care is associated to disease activity, quality of life, work productivity and gender but not disease phenotype: a prospective study in a high-volume IBD center.

J Crohns Colitis 2019 Feb 21. Epub 2019 Feb 21.

First Department of Medicine, Semmelweis University, Budapest, Hungary.

Background And Aims: Measuring quality of care (QoC) in inflammatory bowel diseases (IBD) has become increasingly important, yet complex assessment of QoC from the patients' perspective is rare. We evaluated perceived QoC using the Quality of Care Through the Patient's Eyes - IBD (QUOTE-IBD) questionnaire, and investigated associations between QoC, disease phenotype, work productivity and health-related quality of life (HRQoL) in a high-volume IBD center.

Methods: Consecutive patients attending McGill University Health Centre (MUHC)-IBD Center completed the QUOTE-IBD, Short Inflammatory Bowel Disease Questionnaire (SIBDQ), IBD-Control and Work Productivity and Activity Impairment (WPAI) questionnaires. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz035DOI Listing
February 2019

A Cross-Sectional Study on Malnutrition in Inflammatory Bowel Disease: Is There a Difference Based on Pediatric or Adult Age Grouping?

Inflamm Bowel Dis 2019 Feb 22. Epub 2019 Feb 22.

IBD Research Group, McGill University Health Center, Montreal, Quebec, Canada; Research Centre, Sainte-Justine UHC.

Background: Malnutrition, commonly observed in inflammatory bowel disease (IBD), is associated with increased morbidity and mortality and is attributed to multiple causes. The added energy costs of growth in the child and adolescent with IBD are an additional risk factor.

Methods: The aim of the study was to perform a cross-sectional comparison of nutritional parameters in IBD between pediatric and adult cases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izy403DOI Listing
February 2019

Fight them or feed them: how the intestinal mucus layer manages the gut microbiota.

Gastroenterol Rep (Oxf) 2019 Feb 13;7(1):3-12. Epub 2019 Feb 13.

Wallenberg Laboratory and Sahlgrenska Center for Cardiovascular and Metabolic Research, Department of Molecular and Clinical Medicine, Institute of Medicine, Bruna Stråket 16, University of Gothenburg, SE 413 45 Gothenburg, Sweden.

The intestinal tract is inhabited by a tremendous number of microorganisms, termed the gut microbiota. These microorganisms live in a mutualistic relationship with their host and assist in the degradation of complex carbohydrates. Although the gut microbiota is generally considered beneficial, the vast number of microbial cells also form a permanent threat to the host. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/gastro/goy052DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375348PMC
February 2019

Adverse events in IBD therapy: the 2018 update.

Expert Rev Gastroenterol Hepatol 2018 Dec;12(12):1183-1191

a Department of Medicine, Division of Gastroenterology and Hepatology , University of Maryland School of Medicine , Baltimore , MD , USA.

Introduction: Crohn's disease and ulcerative colitis affect an increasing number of patients, and utilization of immune suppressant and biologic therapies is also increasing. These agents are linked to adverse events ranging from mild nuisance symptoms to potentially life-threatening complications including infections and malignancies. Areas covered: This review provides an updated discussion on adverse events associated with immunomodulator, anti-TNF-α, anti-integrin, and anti-IL 12/IL-23 antibody therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2018.1545574DOI Listing
December 2018

Extraintestinal manifestations in inflammatory bowel disease - epidemiology, genetics, and pathogenesis.

Expert Rev Gastroenterol Hepatol 2019 Feb 4:1-11. Epub 2019 Feb 4.

a Department of Gastroenterology and Hepatology , University Hospital Zurich , Zurich , Switzerland.

Introduction: Inflammatory bowel disease (IBD) is a chronic inflammatory disorder, primarily of, but not restricted to the gut. Extraintestinal manifestations (EIMs) are frequently observed and involve the joints, eyes, hepatobiliary tract, and skin. Areas covered: In this review, we discuss classical EIM focusing on epidemiology, genetics, and pathogenesis, highlighting recent advances in the understanding of EIM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2019.1574569DOI Listing
February 2019

Updates on vaccinating the inflammatory bowel disease patient.

Expert Rev Gastroenterol Hepatol 2019 Mar 21;13(3):229-239. Epub 2019 Jan 21.

b Department of Medicine, Section of Gastroenterology , Boston University School of Medicine , Boston , MA , USA.

Introduction: Many of the therapeutic options for patients with inflammatory bowel disease (IBD) suppress the immune system, which increases the risk of certain infections in these patients. Effective vaccines exist and offer protection against a number of infectious diseases. However, data has shown that IBD patients are inadequately vaccinated and, as a result, are at risk of developing certain preventable infections. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2019.1565993DOI Listing

Nonclinical Toxicology and Toxicokinetic Profile of an Oral Lanthionine Synthetase C-Like 2 (LANCL2) Agonist, BT-11.

Int J Toxicol 2019 Feb 21:1091581819827509. Epub 2019 Feb 21.

1 Landos Biopharma Inc, Blacksburg, VA, USA.

BT-11 is an orally active, gut-restricted investigational therapeutic targeting the lanthionine synthetase C-like 2 pathway with lead indications in ulcerative colitis (UC) and Crohn disease (CD), 2 manifestations of inflammatory bowel disease (IBD). In 5 mouse models of IBD, BT-11 is effective at oral doses of 8 mg/kg. BT-11 was also efficacious at nanomolar concentrations in primary human samples from patients with UC and CD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1091581819827509DOI Listing
February 2019

Construction of a Model Culture System of Human Colonic Microbiota to Detect Decreased Lachnospiraceae Abundance and Butyrogenesis in the Feces of Ulcerative Colitis Patients.

Biotechnol J 2019 Feb 21:e1800555. Epub 2019 Feb 21.

Department of Bioresource Science, Graduate School of Agricultural Science, Kobe University, 1-1 Rokkodai-cho, Nada-ku, Kobe, Hyogo, Japan.

Compositional alteration of the gut microbiota is associated with ulcerative colitis (UC). We established a model culture system for the in vitro human colonic microbiota of UC, which will be helpful for determining medical interventions for the disease. 16S rRNA sequencing confirmed that UC models successfully developed from the fecal inoculum and retained the bacterial species biodiversity of UC feces. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/biot.201800555DOI Listing
February 2019

A retrospective cohort study to evaluate the development of comorbidities, including psychiatric comorbidities, among a pediatric psoriasis population.

Pediatr Dermatol 2019 Feb 21. Epub 2019 Feb 21.

Amgen Inc., Thousand Oaks, California.

Background/objective: Compared with the adult psoriasis population, knowledge about the incidence of comorbidities in the pediatric psoriasis population is limited. The objective of this study was to assess the prevalence and incidence of comorbidities, including psychiatric comorbidities, in patients with pediatric psoriasis.

Methods: In this claims-based, retrospective cohort study, patients with pediatric psoriasis were matched 1:3 with a nonpsoriasis cohort based on age, sex, and index date (the earliest of inpatient claims or the latter of two outpatient claims). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pde.13772DOI Listing
February 2019

Controversies in Inflammatory Bowel Disease: Exploring Clinical Dilemmas Using Cochrane Reviews.

Inflamm Bowel Dis 2019 Feb;25(3):472-478

Robarts Clinical Trials Inc. London, Ontario, Canada.

A symposium organized by the Cochrane IBD Group and presented at the 2017 Digestive Disease Week annual meeting reviewed the recent literature on several controversial topics in inflammatory bowel disease (IBD) management including the efficacy of oral aminosalicylates for induction and maintenance of Crohn's disease (CD), the feasibility of drug withdrawal in patients with quiescent CD, and strategies for detecting colon cancer in patients with IBD. This article summarizes the data presented at that session. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izy268DOI Listing
February 2019

Anti-Saccharomyces Cerevisiae Antibodies as a Prognostic Biomarker in Children with Crohn's disease.

J Pediatr Gastroenterol Nutr 2019 Feb 14. Epub 2019 Feb 14.

Section of Pediatric Gastroenterology, Winnipeg Children's Hospital, Max Rady College of Medicine, Rady Faculty of Health Sciences and Children's Hospital Research Institute, Winnipeg, MB, Canada.

Objective: Although anti-saccharomyces cerevisiae antibodies (ASCA) could be a useful biomarker in differentiating Crohn's disease (CD) from ulcerative colitis (UC), their role as prognostic markers in children with CD has been under-investigated. This longitudinal prospective observational study aimed to assess the prognostic value of ASCA status among children with CD managed using biologics.

Methods: The study population comprised of children with inflammatory bowel disease (IBD) diagnosed with CD from 2012 to 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPG.0000000000002311DOI Listing
February 2019

Response to Vedolizumab for children with steroid refractory Ulcerative Colitis unresponsive to anti-TNF.

Acta Paediatr 2019 Feb 20. Epub 2019 Feb 20.

Bristol Royal Hospital for Children, Upper Maulin Street, Bristol, BS2 8BJ.

Vedolizumab is a humanised monoclonal antibody. This gut specific antibody targets α4β7 integrin which reduces the white cell influx to inflamed tissue. Studies in adults have demonstrated the efficacy of this treatment and in the UK it has been approved by the National Institute for Health and Care Excellence (NICE) for use in adults. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apa.14765DOI Listing
February 2019

Redefining the IBDs using genome-scale molecular phenotyping.

Nat Rev Gastroenterol Hepatol 2019 Feb 20. Epub 2019 Feb 20.

Center for Gastrointestinal Biology and Disease, Department of Genetics, University of North Carolina, Chapel Hill, NC, USA.

The IBDs, Crohn's disease and ulcerative colitis, are chronic inflammatory conditions of the gastrointestinal tract resulting from an aberrant immune response to enteric microbiota in genetically susceptible individuals. Disease presentation and progression within and across IBDs, especially Crohn's disease, are highly heterogeneous in location, severity of inflammation and other phenotypes. Current clinical classifications fail to accurately predict disease course and response to therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41575-019-0118-xDOI Listing
February 2019

Members of the endocannabinoid system are distinctly regulated in inflammatory bowel disease and colorectal cancer.

Sci Rep 2019 Feb 20;9(1):2358. Epub 2019 Feb 20.

Otto Loewi Research Center, Division of Pharmacology, Medical University of Graz, Graz, Austria.

Preclinical studies have demonstrated that the endocannabinoid system (ECS) plays an important role in the protection against intestinal inflammation and colorectal cancer (CRC); however, human data are scarce. We determined members of the ECS and related components of the 'endocannabinoidome' in patients with inflammatory bowel disease (IBD) and CRC, and compared them to control subjects. Anandamide (AEA) and oleoylethanolamide (OEA) were increased in plasma of ulcerative colitis (UC) and Crohn's disease (CD) patients while 2-arachidonoylglycerol (2-AG) was elevated in patients with CD, but not UC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-019-38865-4DOI Listing
February 2019

Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease.

Aliment Pharmacol Ther 2019 Feb 19. Epub 2019 Feb 19.

Department of Gastroenterology, University Medical Centre Ljubljana, Ljubljana, Slovenia.

Background: Combination treatment with azathioprine for 6-12 months is the preferred strategy for starting infliximab due to improved pharmacokinetics. However, optimised infliximab monotherapy with proactive dose escalations in case of low trough levels is a safer but under-studied alternative.

Aim: To compare the clinical success and infliximab consumption of combination vs optimised monotherapy strategies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15179DOI Listing
February 2019

Aggravated mucosal and immune damage in a mouse model of ulcerative colitis with stress.

Exp Ther Med 2019 Mar 9;17(3):2341-2348. Epub 2019 Jan 9.

Department of Gastroenterology, Tianjin Nankai Hospital, Tianjin 300100, P.R. China.

The aim of the present study was to determine the influence of stress on the colonic mucosa and immune system and to further investigate the association between stress and development and pathogenesis of ulcerative colitis (UC). Mice were treated with 2,4,6-trinitrobenzenesulfonic acid to induce an animal model of UC, and stress was induced by water immersion and restraint. Subsequently, the disease activity index (DAI), secretory immunoglobulin A (sIgA), IgA, interleukin (IL)-6 and -8, tumor necrosis factor-α (TNF-α), complement component (C)3 and C4, and alterations in the colonic mucosa were observed. Read More

View Article

Download full-text PDF

Source
http://www.spandidos-publications.com/10.3892/etm.2019.7162
Publisher Site
http://dx.doi.org/10.3892/etm.2019.7162DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364228PMC
March 2019
1 Read

Efficacy of biological drugs in short-duration versus long-duration inflammatory bowel disease: a protocol for a systematic review and an individual-patient level meta-analysis of randomised controlled trials.

BMJ Open 2019 Jan 25;9(1):e024222. Epub 2019 Jan 25.

Department of Gastroenterology, First affiliated Hospital of the Sun Yatsen University, Guangzhou, China.

Introduction: Crohn's disease (CD) and ulcerative colitis (UC) are remitting-relapsing inflammatory diseases often culminating in disease complications and/or need for surgery. Biologic monoclonal antibody drugs ('Biologics') are efficacious for both diseases, but there are no systematic assessments of their efficacy if administered early after disease onset ('top-down' strategy) vis-à-vis later in the course of disease ('step-up' approach).

Methods And Analysis: Electronic databases (MEDLINE, EMBASE/EMBASE classic Cochrane CENTRAL register of controlled trials, the Cochrane IBD Group Specialised Trials Register and Clinicaltrials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bmjopen-2018-024222DOI Listing
January 2019

A comprehensive review and update on ulcerative colitis foreword.

Authors:
Jerrold B Leikin

Dis Mon 2019 Feb 16. Epub 2019 Feb 16.

Clinical Professor of Medicine Pritzker School of Medicine, University of Chicago, Chicago, Il. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.disamonth.2019.02.005DOI Listing
February 2019

Treatment with Noripurum EV is effective and safe in pediatric patients with inflammatory bowel disease and iron deficiency anemia.

Scand J Gastroenterol 2019 Feb 20:1-7. Epub 2019 Feb 20.

a Pediatric Gastroenterology, Pediatric Department , Escola Paulista de Medicina, Universidade Federal de São Paulo , São Paulo , Brasil.

Objectives: To evaluate the therapeutic response and adverse effects of Noripurum EV in children and adolescents with inflammatory bowel disease (IBD) and iron deficiency anemia.

Materials And Methods: Cohort study involving patients with Crohn's disease (CD) and ulcerative colitis (UC) who received treatment for iron deficiency anemia with Noripurum EV. Anemia was defined according to WHO 2011 criteria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/00365521.2019.1570326DOI Listing
February 2019

Mechanisms and management of growth impairment in children affected by inflammatory bowel disease.

Expert Rev Endocrinol Metab 2013 May;8(3):289-299

a Department of Pediatrics, University of Milan, Luigi Sacco Hospital, Milan, Italy.

Growth failure is a typical complication of pediatric inflammatory bowel disease. Factors responsible for stunting are multiple, and proinflammatory cytokines such as TNF-α and IL-6 play a pivotal role. Other determinants are disease severity and location, malnutrition, increased nutritional needs, genetics and drugs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/eem.13.12DOI Listing

MicroRNA-31 Reduces Inflammatory Signaling and Promotes Regeneration in Colon Epithelium, and Delivery of Mimics in Microspheres Reduces Colitis in Mice.

Gastroenterology 2019 Feb 16. Epub 2019 Feb 16.

State Key Laboratories for Agrobiotechnology and Beijing Advanced Innovation Center for Food Nutrition and Human Health and, College of Biological Sciences, China Agricultural University, Beijing, China. Electronic address:

Background & Aims: Levels of microRNA 31 (MIR31) are increased in intestinal tissues from patients with inflammatory bowel diseases and colitis-associated neoplasias. We investigated the effects of this microRNA on intestinal inflammation by studying mice with colitis.

Methods: We obtained colon biopsy samples from 82 patients with ulcerative colitis (UC), 79 patients with Crohn's disease (CD), and 34 healthy individuals (controls) at Shanghai Tenth People's Hospital. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.gastro.2019.02.023DOI Listing
February 2019

Porous polymeric microparticles as an oral drug platform for effective ulcerative colitis treatment.

J Pharm Sci 2019 Feb 16. Epub 2019 Feb 16.

Education Ministry Key Laboratory on Luminescence and Real-Time Analysis, Faculty of Materials and Energy, Southwest University, Beibei, Chongqing 400715, P.R. China. Electronic address:

Porous microparticles (MPs) have been regarded as a promising vehicle for drug delivery. Herein, porous MPs and their counterparts (non-porous MPs) were produced by a conventional emulsion-solvent evaporation method in the presence and absence of ammonium bicarbonate, and curcumin (CUR) was encapsulated into these MPs during the preparation process. The obtained MPs possessed desirable diameters of around 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.xphs.2019.02.001DOI Listing
February 2019

Co-existent ulcerative colitis and Guillain-Barré syndrome: a case report and literature review.

Clin J Gastroenterol 2019 Feb 18. Epub 2019 Feb 18.

Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, 1-757, Aasahimachi-Dori, Chuo-Ku, Niigata, Niigata, 9518510, Japan.

Ulcerative colitis (UC) is a chronic and recurrent inflammatory disease involving the intestine, and Guillain-Barré Syndrome (GBS) is rapid-onset muscle weakness caused by the immune system damaging the peripheral nervous system. UC and GBS can be caused by immune system abnormalities and can co-exist. To date, there are 7 reported cases of GBS in patients with UC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12328-019-00939-1DOI Listing
February 2019

Analysis of pH Dose-dependent Growth of Sulfate-reducing Bacteria.

Open Med (Wars) 2019 16;14:66-74. Epub 2019 Jan 16.

Department of Experimental Biology, Faculty of Science, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic.

Lower intraluminal colonic pH is an indication for the development of inflammatory bowel disease including active ulcerative colitis. Involvement of intestinal sulfate-reducing bacteria in decreasing bowel pH by the production of HS and acetate as well as their sensitivity has never been reported before. The study of the relative pH and survival of Vib-7 by monitoring sulfate reduction parameters was the aim of this work. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1515/med-2019-0010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371204PMC
January 2019

Central Venous Sinus Thrombosis in a Boy With Acute Severe Ulcerative Colitis.

Front Pediatr 2019 1;7:19. Epub 2019 Feb 1.

Pediatric Gastroenterology and Nutrition Unit, Hospital Regional Universitario de Malaga, Málaga, Spain.

Cerebral venous sinus thrombosis (CVST) in childhood is uncommon. Certain diseases predispose patients to CVST, such as inflammatory bowel disease (IBD), which is considered a risk factor for developing thrombosis, which in turn is considered an extraintestinal manifestation of IBD. The use of prophylaxis in certain patients is a controversial topic. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fped.2019.00019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367252PMC
February 2019

Effect of Irritable Bowel Syndrome on Sleep Quality and Quality of Life of Inflammatory Bowel Disease in Clinical Remission.

Int J Prev Med 2019 15;10:10. Epub 2019 Jan 15.

Department of Internal Medicine, Metabolic Diseases Research Center, Qazvin University of Medical Sciences, Qazvin, Iran.

Background: Inflammatory bowel disease (IBD) as a chronic and debilitating disease is affected by sleep disturbance which increases the risk of malignancy. Sleep disturbance is more common in irritable bowel syndrome (IBS) and few reported studies have assessed its role in IBD. We evaluated the effect of IBS on sleep quality and quality of life (QOL) of IBD patients in clinical remission. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijpvm.IJPVM_364_17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360848PMC
January 2019
1 Read

Inducible nitric oxide synthase as a potential blood-based biomarker in inflammatory bowel diseases.

Gastroenterol Hepatol Bed Bench 2018 ;11(Suppl 1):S124-S128

Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Aim: Here, we evaluated the role of (iNOS) as a blood-based biomarker of inflammatory bowel diseases (IBD).

Background: Up-regulation of inducible nitric oxide synthase (iNOS) in the intestinal epithelial cells has been closely associated with the initiation and maintenance of intestinal inflammation in IBD.

Methods: In a case-control design, 59 IBD patients and 30 healthy control subjects were participated in this study. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347994PMC
January 2018

Evaluation of IL-12A, IL-12B, IL-23A and IL-27 mRNA expression level genes in peripheral mononuclear cells of inflammatory bowel disease patients in an Iranian population.

Gastroenterol Hepatol Bed Bench 2018 ;11(Suppl 1):S45-S52

Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Aim: Aim of this study was to compare the gene expression of Interleukin 12 members in two phase of IBD.

Background: Inflammatory bowel disease (IBD) is a well-known gastrointestinal disorder in the world that fluctuates between remission and flare-up phases. Each of these phases has an individual immune system response profile. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347999PMC
January 2018

Determining the degree of adherence to treatment in inflammatory bowel disease patients.

Gastroenterol Hepatol Bed Bench 2018 ;11(Suppl 1):S39-S44

Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Aim: Since the inflammatory bowel disease (IBD) is a disorder which requires continuous drug intake to induce and maintain the remission phase, finding the barriers for low adherent group, may improve the disease phase and quality of life in those patients.

Background: IBD is defined as a chronic immune disorder with unpredictable flares. The common treatment of these diseases can be effective for inducing and maintaining remission courses. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347981PMC
January 2018
1 Read

Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease.

Front Pharmacol 2019 1;10:39. Epub 2019 Feb 1.

Department of Medicine 1, Friedrich-Alexander-Universität Erlangen-Nürnberg, Kussmaul Campus for Medical Research and Translational Research Center, Erlangen, Germany.

Anti-integrin therapy is a new frontline strategy in the treatment of inflammatory bowel diseases (IBD). The anti-β7 integrin antibody etrolizumab is currently being investigated for safety and efficacy in Crohn's disease (CD) and ulcerative colitis (UC) in several phase III trials. Mechanistically, etrolizumab is known to block β7 integrin ligand binding and reduces intestinal trafficking of β7-expressing cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fphar.2019.00039DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367223PMC
February 2019

Fecal microbiota profiles in treatment-naïve pediatric inflammatory bowel disease - associations with disease phenotype, treatment, and outcome.

Clin Exp Gastroenterol 2019 31;12:37-49. Epub 2019 Jan 31.

Department of Pediatrics, Oslo University Hospital, Ullevål, Oslo, Norway.

Purpose: Imbalance in the microbiota, dysbiosis, has been identified in inflammatory bowel disease (IBD). We explored the fecal microbiota in pediatric patients with treatment-naïve IBD, non-IBD patients with gastrointestinal symptoms and healthy children, its relation to IBD subgroups, and treatment outcomes.

Patients And Methods: Fecal samples were collected from 235 children below 18 years of age. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CEG.S186235DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362922PMC
January 2019

Fatigue in children and adolescents with inflammatory bowel disease.

World J Gastroenterol 2019 Feb;25(5):632-643

Department of Paediatric Gastroenterology, Hepatology and Nutrition, University Medical Center Groningen, Groningen 9713 GZ, The Netherlands.

Aim: To identify factors other than active disease and anemia that contribute to fatigue in pediatric inflammatory bowel disease (IBD).

Methods: We performed an electronic search in Medline and EMBASE from their inception to May 2017 using the search term "fatigue" or the related keywords "physical impairment" and "inflammatory bowel disease" with the filter "child" (age 0-18 years). Cross-sectional and case-control studies were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3748/wjg.v25.i5.632DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371006PMC
February 2019

Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study.

Aliment Pharmacol Ther 2019 Feb 17. Epub 2019 Feb 17.

Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts.

Background: The older patient group with inflammatory bowel diseases (IBD) is particularly vulnerable to consequences of disease and therapy-related side effects but little is known about the best treatment options in this population.

Aim: To compare safety and efficacy of tumor necrosis factor α antagonist (anti-TNF) or vedolizumab (VDZ) in patients with IBD >60 years of age.

Methods: This retrospective study included patients with Crohn's disease (CD) or ulcerative colitis (UC) initiating anti-TNF or VDZ therapy ≥60 years of age at three study sites. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15177DOI Listing
February 2019
1 Read

Sex-based differences in the incidence of inflammatory bowel diseases-pooled analysis of population-based studies from the Asia-Pacific region.

Aliment Pharmacol Ther 2019 Feb 17. Epub 2019 Feb 17.

The Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York City, New York.

Background: There appear to be differences in risk factor profiles for IBD between Asia-Pacific and Western populations, which might suggest idiosyncrasies in pathogenesis. Recently, sex-based differences in IBD according to the age of diagnosis have been described in Western populations.

Aim: Our primary aim was to identify whether sex-based differences in IBD incidence similarly exist across the age spectrum for Asia-Pacific populations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15178DOI Listing
February 2019
1 Read

Untargeted Metabolomics and Inflammatory Markers Profiling in Children With Crohn's Disease and Ulcerative Colitis-A Preliminary Study.

Inflamm Bowel Dis 2019 Feb 17. Epub 2019 Feb 17.

Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland.

Background: Metabolic profiling might be used to identify disease biomarkers. The aim of our study was to determine the usefulness of untargeted metabolomics analysis to detect differences in serum metabolites between newly diagnosed and untreated pediatric patients with Crohn's disease (CD) or ulcerative colitis (UC) in comparison with a control group (Ctr). Moreover, we investigated the potential of profiling metabolomics and inflammatory markers to improve the noninvasive diagnosis of CD and UC in children. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ibd/izy402DOI Listing
February 2019
1 Read

Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trial.

BMJ Open 2019 Feb 15;9(2):e023765. Epub 2019 Feb 15.

Division of Gastroenterology and Hepatology, Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK.

Introduction: Acute severe ulcerative colitis (ASUC) is a severe manifestation of ulcerative colitis (UC) that warrants hospitalisation. Despite significant advances in therapeutic options for UC and in the medical management of steroid-refractory ASUC, the initial treatment paradigm has not changed since 1955 and is based on the use of intravenous corticosteroids. This treatment is successful in approximately 50% of patients but failure of this and subsequent medical therapy still occurs, with colectomy rates of up to 40% reported. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bmjopen-2018-023765DOI Listing
February 2019
1 Read

Role of eosinophils in a murine model of inflammatory bowel disease.

Biochem Biophys Res Commun 2019 Feb 13. Epub 2019 Feb 13.

Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Hyogo, Japan.

Ulcerative colitis (UC) is a form of inflammatory bowel disease (IBD), which is triggered spontaneously by unknown mechanisms and manifests as chronic and relapsing inflammatory conditions in the colon. Eosinophil infiltration is often observed in the colonic tissue of ulcerative colitis patients. However, the role of eosinophils in the disease has not been well defined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2019.02.056DOI Listing
February 2019
1 Read

Colocutaneous fistula through ulcerative colitis and cancer to the pyoderma gangrenosum: a never-ending story for a single patient. Case report.

G Chir 2019 Jan-Feb;40(1):39-43

Background: Inflammatory bowel diseases may be associated with many extraintestinal complications, that in some cases can represent the first onset of these disorders. In particular during the course of the disease, Ulcerative Colitis develops extraintestinal manifestations very frequently. One of the rarest is pyoderma gangrenosum, a noninfectious neuthrophilic dermatosis, that can involve most commonly legs but also other parts of the skin or mucosas. Read More

View Article

Download full-text PDF

Source
February 2019
1 Read

Thrombotic complications in inflammatory bowel diseases.

G Chir 2019 Jan-Feb;40(1):14-19

Inflammatory bowel disease (IBD), Crohn's Disease (CD) and Ulcerative Colitis (UC) are associated with an increased risk of arterial and venous thromboembolism. A 2 to 3 time fold increased risk of developing thromboembolic complications was reported for IBD patients compared to general population. A systematic literature search was conducted using PubMed, Medline, Scopus, Cochrane database. Read More

View Article

Download full-text PDF

Source
February 2019

iTRAQ-based pharmacoproteomics reveals potential targets of berberine, a promising therapy for ulcerative colitis.

Eur J Pharmacol 2019 Feb 13. Epub 2019 Feb 13.

Hong Kong Baptist University Shenzhen Research Institute and Continuing Education, Shenzhen, China; Laboratory of Brain and Gut Research, Hong Kong Chinese Medicine Research Center, School of Chinese Medicine, Hong Kong, China. Electronic address:

Previous studies by us and others have indicated that berberine is a promising therapy for ulcerative colitis (UC). However, the mechanisms of UC and the therapeutic targets of berberine are poorly understood. iTRAQ-based proteomics was utilized to characterize the proteins and pathways associated with the development of colitis and its improvement after berberine treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejphar.2019.02.021DOI Listing
February 2019
2 Reads

Short-term Results After Totally Robotic Restorative Total Proctocolectomy With Ileal Pouch Anal Anastomosis for Ulcerative Colitis.

Surg Laparosc Endosc Percutan Tech 2019 Feb 12. Epub 2019 Feb 12.

Department of General Surgery, School of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey.

In this study, we aimed to present our initial experience on totally robotic total restorative proctocolectomy in ulcerative colitis (UC) patients. Patients undergoing a totally robotic restorative total proctocolectomy with ileal J-pouch anal anastomosis for UC between January 2015 and November 2017 were included. The da Vinci Xi was used for the operations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/SLE.0000000000000645DOI Listing
February 2019

Real-world effectiveness and safety of Vedolizumab for the treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.

J Crohns Colitis 2019 Feb 14. Epub 2019 Feb 14.

Department of Gastroenterology, Raigmore Hospital, Inverness.

Introduction: Vedolizumab is an anti-a4b7 monoclonal antibody that is licensed for the treatment of moderate to severe Crohn's disease and ulcerative colitis.

Aims: To establish the real-world efficacy and safety of vedolizumab in the treatment of inflammatory bowel disease.

Methods: Retrospective study involving six NHS health boards in Scotland between June 2015 and November 2017. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/ecco-jcc/advance-article/doi/10.109
Publisher Site
http://dx.doi.org/10.1093/ecco-jcc/jjz042DOI Listing
February 2019
1 Read

Loss of RUNX3 Immunoreactivity in Non-Neoplastic Rectal Mucosa May Predict the Occurrence of Ulcerative Colitis-Associated Colorectal Cancer.

Digestion 2019 Feb 14:1-9. Epub 2019 Feb 14.

Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan.

Background/aims: Runt-related transcription factor (RUNX) 3 is a tumor suppressor whose expression is reduced in non-neoplastic rectal mucosa of patients with ulcerative colitis (UC) with coexisting colitis-associated cancer (CAC). We aimed to evaluate RUNX3 utility as a predictive marker for CAC using immunohistochemistry (IHC) for non-neoplastic UC mucosa.

Methods: We retrospectively compared the RUNX3 expression detected by IHC between non-neoplastic rectal biopsy specimens from 20 cases with invasive cancer (CAC group) and 20 cases selected from 138 patients without CAC (non-CAC group) that were treated during the same period (2006-2017) and were matched for sex, duration, extension, and age. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/497272
Publisher Site
http://dx.doi.org/10.1159/000497272DOI Listing
February 2019
1 Read

Expansion of Bacteriophages Is Linked to Aggravated Intestinal Inflammation and Colitis.

Cell Host Microbe 2019 Feb;25(2):285-299.e8

Department of Pathology, Division of Microbiology and Immunology, University of Utah School of Medicine, Salt Lake City, UT 84112, USA. Electronic address:

Bacteriophages are the most abundant members of the microbiota and have the potential to shape gut bacterial communities. Changes to bacteriophage composition are associated with disease, but how phages impact mammalian health remains unclear. We noted an induction of host immunity when experimentally treating bacterially driven cancer, leading us to test whether bacteriophages alter immune responses. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.chom.2019.01.008DOI Listing
February 2019
2 Reads
12.328 Impact Factor

Sex Differences in Treatment Strategies Among Patients With Ulcerative Colitis: A Retrospective Cohort Analysis of Privately Insured Patients.

Dis Colon Rectum 2019 Feb 8. Epub 2019 Feb 8.

S-SPIRE Center, Department of Surgery, Stanford University, Stanford, California.

Background: Sex-based treatment disparities occur in many diseases. Women undergo fewer procedural interventions, and their care is less consistent with guideline-based therapy. There is limited research exploring sex-based differences in ulcerative colitis treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/DCR.0000000000001342DOI Listing
February 2019
7 Reads